[H-3] VERAPAMIL BINDING TO RAT CARDIAC SARCOLEMMAL MEMBRANE-FRAGMENTS - AN EFFECT OF ISCHEMIA

被引:20
作者
DILLON, JS [1 ]
NAYLER, WG [1 ]
机构
[1] UNIV MELBOURNE,AUSTIN HOSP,DEPT MED,HEIDELBERG,VIC 3084,AUSTRALIA
关键词
D O I
10.1111/j.1476-5381.1987.tb16829.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:99 / 109
页数:11
相关论文
共 51 条
[21]   THE USE OF LIGAND-BINDING FOR THE CHARACTERIZATION OF ALPHA-ADRENOCEPTORS [J].
GLOSSMANN, H ;
HORNUNG, R ;
PRESEK, P .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1980, 2 :S303-S324
[22]  
GLOSSMANN H, 1985, J CARDIOVASC PHARM, V7, P520
[23]   [H-3]NITRENDIPINE-LABELED CALCIUM CHANNELS DISCRIMINATE INORGANIC CALCIUM AGONISTS AND ANTAGONISTS [J].
GOULD, RJ ;
MURPHY, KMM ;
SNYDER, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (11) :3656-3660
[24]   CHARACTERIZATION OF (H-3)NIFEDIPINE BINDING-SITES IN RABBIT MYOCARDIUM [J].
HOLCK, M ;
THORENS, S ;
HAEUSLER, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1982, 85 (3-4) :305-315
[25]   DOES [H-3]-LABELED NIFEDIPINE LABEL THE CALCIUM-CHANNEL IN RABBIT MYOCARDIUM [J].
HOLCK, M ;
THORENS, S ;
HAEUSLER, G .
JOURNAL OF RECEPTOR RESEARCH, 1983, 3 (1-2) :191-198
[26]  
HULTHEN UL, 1982, J CARDIOVASC PHARM, V4, pS291
[27]   SITES OF ACTION OF CA-2+ CHANNEL INHIBITORS [J].
JANIS, RA ;
SCRIABINE, A .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (23) :3499-3507
[28]   1,4-DIHYDROPYRIDINE CA-2+ CHANNEL ANTAGONISTS AND ACTIVATORS - A COMPARISON OF BINDING CHARACTERISTICS WITH PHARMACOLOGY [J].
JANIS, RA ;
TRIGGLE, DJ .
DRUG DEVELOPMENT RESEARCH, 1984, 4 (03) :257-274
[29]   BINDING OF [H-3]-LABELED NIMODIPINE TO CARDIAC AND SMOOTH-MUSCLE MEMBRANES [J].
JANIS, RA ;
MAURER, SC ;
SARMIENTO, JG ;
BOLGER, GT ;
TRIGGLE, DJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1982, 82 (3-4) :191-194
[30]   VERAPAMIL COMPETITIVELY INHIBITS ALPHA-1-ADRENERGIC AND MUSCARINIC BUT NOT BETA-ADRENERGIC RECEPTORS IN RAT MYOCARDIUM [J].
KARLINER, JS ;
MOTULSKY, HJ ;
DUNLAP, J ;
BROWN, JH ;
INSEL, PA .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1982, 4 (03) :515-520